We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+23.8%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$239M
AUM Growth
+$38.5M
Cap. Flow
+$5.11M
Cap. Flow %
2.14%
Top 10 Hldgs %
60.96%
Holding
53
New
9
Increased
15
Reduced
7
Closed
12

Top Buys

Rank Stock Value
1
ARDX icon
Ardelyx
ARDX
+$4.64M
2
CORI
Corium International, Inc.
CORI
+$3.29M
3
XLRN
Acceleron Pharma
XLRN
+$2.9M
4
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$2.83M
5
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$2.55M

Top Sells

Rank Stock Value
1
TVRD
Tvardi Therapeutics
TVRD
+$7.08M
2
OCUL icon
Ocular Therapeutix
OCUL
+$5.1M
3
SAGE
Sage Therapeutics
SAGE
+$3.2M
4
GNMX
Aevi Genomic Medicine Inc
GNMX
+$1.99M
5
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$1.96M

Sector Composition

Rank Sector Weight
1 Healthcare 98.92%
2 Miscellaneous 1.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
1
DELISTED
Blueprint Medicines
BPMC
$44.6M 18.63%
880,000
– –
AXGN icon
2
Axogen
AXGN
$2.78B
$33M 13.78%
1,970,000
– –
KYNB
3
Kyntra Bio
KYNB
$32.4M
$11.6M 4.86%
14,400
+1,200
+9% +$836K
LOXO
4
DELISTED
Loxo Oncology, Inc
LOXO
$10.4M 4.35%
130,000
– –
SBBP
5
DELISTED
Strongbridge Biopharma plc.
SBBP
$8.44M 3.52%
1,180,000
– –
CDXS icon
6
Codexis
CDXS
$182M
$8.01M 3.35%
1,470,000
+300,000
+26% +$1.38M
IMMU
7
DELISTED
Immunomedics Inc
IMMU
$7.95M 3.32%
900,000
-60,000
-6% -$421K
MNTA
8
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$7.61M 3.18%
450,000
+10,000
+2% +$152K
TBPH icon
9
Theravance Biopharma
TBPH
$885M
$7.17M 3%
180,000
– –
CTMX icon
10
CytomX Therapeutics
CTMX
$745M
$7.13M 2.98%
460,000
+120,000
+35% +$1.81M
CMRX
11
DELISTED
Chimerix, Inc.
CMRX
$6.98M 2.91%
1,280,000
+65,000
+5% +$342K
NVLN
12
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$6.92M 2.89%
750,000
+20,000
+3% +$193K
AGIO icon
13
Agios Pharmaceuticals
AGIO
$2.05B
$6.69M 2.79%
130,000
– –
CORI
14
DELISTED
Corium International, Inc.
CORI
$5.33M 2.23%
715,000
+553,000
+341% +$3.29M
FOMX
15
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$5.27M 2.2%
1,135,000
+635,000
+127% +$2.83M
SGMO
16
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$5.1M 2.13%
580,000
-1,000
-0.2% -$6.42K
ADMS
17
DELISTED
Adamas Pharmaceuticals
ADMS
$5.07M 2.12%
290,000
– –
EGRX
18
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$4.73M 1.98%
60,000
+10,000
+20% +$818K
PRTA icon
19
Prothena Corp
PRTA
$467M
$4.6M 1.92%
85,000
-2,100
-2% -$112K
ENTA icon
20
Enanta Pharmaceuticals
ENTA
$402M
$3.6M 1.5%
100,000
– –
NDRM
21
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$3.6M 1.5%
120,300
+300
+0.3% +$7.77K
XLRN
22
DELISTED
Acceleron Pharma
XLRN
$3.04M 1.27%
+100,000
New +$2.9M
BOLD
23
DELISTED
Audentes Therapeutics, Inc
BOLD
$2.87M 1.2%
+150,000
New +$2.4M
HROW icon
24
Harrow
HROW
$1.44B
$2.86M 1.2%
895,000
+34,500
+4% +$127K
ARDX icon
25
Ardelyx
ARDX
$986M
$2.79M 1.16%
+546,500
New +$4.64M
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2017 Portfolio in Review

As of Q2 2017, Opaleye Management held 53 positions worth $239M, up 19% from $201M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Opaleye Management's Q2 2017 filing shows 9 new, 15 increased, 7 reduced and 12 closed positions. Its largest new stake was Ardelyx: 546,500 shares worth $2.79M. The largest sale was Tvardi Therapeutics, an estimated $7.08M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q2 2017 buy was Ardelyx: 546,500 shares worth $2.79M.
  • Opaleye Management added most to Corium International, Inc. in Q2 2017, an estimated $3.29M increase.
  • Opaleye Management's biggest Q2 2017 reduction was PDS Biotechnology, cutting an estimated $1.48M.
  • Opaleye Management fully exited Tvardi Therapeutics in Q2 2017, selling an estimated $7.08M.
  • Opaleye Management's ten largest holdings make up 61% of its $239M portfolio in Q2 2017.
  • Opaleye Management opened 9 new positions and closed 12 in Q2 2017.
  • Opaleye Management's portfolio value rose 19% quarter-over-quarter to $239M.

Based on Opaleye Management's 13F filing for Q2 2017, filed 14 Aug 2017.